You are viewing: UK AI in Oncology Market analysis
Part of: AI in Oncology Market (Global)

The UK AI in Oncology Market was valued at $131.3 Million in 2024 and projected to reach to $646.4 Million by 2029, representing a compound annual growth rate of 30.4%. The UK AI in Oncology Market is positioned for exceptional growth through 2029, driven by NHS digitalization efforts, regulatory support for AI medical devices, and increasing collaboration between tech companies and healthcare providers.

UK AI in Oncology Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK AI in Oncology Market Trends and Insights

  • The UK's advanced healthcare infrastructure, strong investment in digital health technologies, and increasing adoption of AI-driven diagnostic and treatment solutions are driving this accelerated growth.
  • The UK's commitment to precision medicine and cancer care innovation positions it as a leading European market for AI oncology applications. During the 2024-2029 forecast period, the UK market will benefit from rising demand for AI-powered imaging analysis, predictive analytics, and personalized treatment planning.
  • The UK's regulatory environment and NHS integration of AI tools are facilitating faster deployment of oncology AI solutions.
  • Key drivers include growing cancer incidence, shortage of oncology specialists, and substantial government and private sector funding for AI healthcare initiatives across the UK..

Key Market Statistics

  • CAGR (2024-2029) 30.4% CAGR
  • Market Size, 2024 ~USD 131.3 Million
  • Forecast, 2029 ~USD 646.4 Million
  • Country UK

UK AI in Oncology Market Overview

Rapid Market Expansion :

The UK AI in Oncology Market is projected to grow from $131.3 million in 2024 to $646.4 million by 2029, demonstrating a robust 30.4% CAGR, outpacing the global average of 29.4%.

Advanced Healthcare Infrastructure :

The UK's NHS digital transformation initiatives and established healthcare IT ecosystem provide a strong foundation for AI adoption in cancer diagnosis, treatment planning, and patient management systems.

Increased Investment in Digital Health :

UK government funding and private sector investment in AI-driven oncology solutions are accelerating, with major healthcare institutions prioritizing precision medicine and early cancer detection technologies.

Growing Clinical Adoption :

UK hospitals and cancer centers are increasingly implementing AI algorithms for pathology analysis, imaging interpretation, and personalized treatment recommendations, improving patient outcomes and operational efficiency.

UK AI in Oncology Market Dynamics

  • The market benefits from the UK's strong research institutions, favorable reimbursement policies, and growing patient demand for precision oncology solutions. Key growth catalysts include expanding AI applications in early cancer detection, real-world evidence generation, and treatment optimization.
  • Investment in AI infrastructure, coupled with skilled workforce development and data governance frameworks, will further accelerate market penetration across UK healthcare systems, positioning the nation as a leader in AI-enabled cancer care..

Related Ecosystem

Healthcare Analytics

Top Technologies
  • Machine Learning
  • Natural Language Processing (NLP)
  • Blood Pressure Monitors
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
Top Companies
  • Oracle Corporation
  • PHILIPS HEALTHCARE
  • Siemens healthineers
  • Zensar Technologies Limited
  • EPIC SYSTEMS CORPORATION

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Key Takeaways

      • The UK AI in Oncology Market is valued at $131.3 million in 2024 and is projected to grow to $646.4 million by 2029 at a 30.4% CAGR.
      • The UK's advanced healthcare infrastructure and NHS digital transformation initiatives are accelerating AI adoption in cancer diagnosis and treatment.
      • Rising cancer prevalence and oncologist shortages in the UK are driving demand for AI-powered diagnostic and decision-support tools.
      • Strong government funding and regulatory support in the UK are enabling rapid commercialization and clinical integration of AI oncology solutions.

      AI in Oncology Market Report Scope

      Report Metric Details
      Base Year 2024
      Fastest Growing Segment DEEP LEARNING (Type)
      Forecast Period 2024-2029
      Growth Rate CAGR of 29.4% from 2024 to 2029
      Largest Segment SOLID TUMORS (Cancer Type)
      Market Size Base Year (Billions) ~USD 2.45 (2024)
      Revenue Forecast (Billions) ~USD 8.9 (2029)
      Segments Covered Technology, Type, Application, Cancer Type, End User, Player Type, Deployment Model

      UK AI in Oncology Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Technology

      • Computer Vision
      • Context-Aware Processing & Computing
      • Image Analysis
      • Machine Learning
      • Natural Language Processing
      • Natural Language Processing (Nlp)

      By Type

      • Adaptive Trial Design & Monitoring
      • AI-Guided Drug Delivery
      • Brain Tumors
      • Breast Cancer
      • Candidate Selection & Validation
      • Chemotherapy
      • Clinical Trial Optimization
      • Colorectal Cancer
      • Combination & Dose Optimization
      • Computed Tomography
      • Computed Tomography (Ct)
      • Deep Learning
      • Digital Pathology & Histopathology
      • Genetic Risk Prediction
      • Hit Identification & Prioritization
      • Hit-To-Lead Identification/Lead Generation
      • Hospitals & Clinics
      • Imaging & Radiology
      • Immunotherapy
      • Intraoperative Guidance & Robotics
      • Intraoperative Guidance And Robotics
      • Laboratories & Diagnostic Centers
      • Lead Optimization
      • Leukemia
      • Liquid Biopsy & Biomarker Detection
      • Long-Term Prediction
      • Lung Cancer
      • Lymphoma
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mental Health & Support Systems
      • Multiple Myeloma
      • Nuclear Imaging
      • Other Healthcare Providers
      • Other Hematologic Malignancies
      • Other Hematological Malignancies
      • Other Imaging Modalities
      • Other Machine Learning Technologies
      • Other Solid Tumors
      • Other Tumors
      • Others Healthcare Providers
      • Patient Education & Empowerment
      • Personalized Treatment Planning
      • Postoperative Analysis & Recovery
      • Precision Medicine & Genomic Analysis
      • Preclinical Testing
      • Predictive Modeling For Human Trials
      • Predictive Modelling For Human Trials
      • Predictive Models For Treatment Response
      • Preoperative Imaging & 3D Modeling
      • Preoperative Imaging And 3D Modeling
      • Prostate Cancer
      • Radiation Therapy
      • Radiomics & Radiogenomics
      • Radiomics And Radiogenomics
      • Recurrence Monitoring
      • Reinforcement Learning
      • Remote Patient Monitoring
      • Specialty Centers
      • Supervised Learning
      • Surgical Planning & Assistance
      • Symptom Management & Virtual Assistance
      • Target Identification & Validation
      • Targeted Therapy
      • Treatment Recommendation Systems
      • Ultrasound
      • Unsupervised Learning
      • X-Ray Imaging

      By Application

      • Data Management & Analytics
      • Diagnosis & Early Detection
      • Drug Development
      • Drug Discovery
      • Other Applications
      • Patient Engagement & Remote Monitoring
      • Post Treatment Surveillance & Survivorship Care
      • Post-Treatment Surveillance & Survivorship Care
      • Treatment Planning & Personalization

      By Cancer Type

      • Hematologic Malignancies
      • Hematological Malignancies
      • Other Cancer Types
      • Other Cancers
      • Others Cancer Types
      • Solid Tumors

      By End User

      • Academic & Research Institutions
      • Government & Regulatory Agencies
      • Healthcare Payers
      • Healthcare Providers
      • Medical Device/ Equipment Companies
      • Medical Device/Equipment Companies
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      By Player Type

      • Business Process Service Providers
      • Integrated Suite/Platform Providers
      • Niche/Point Solution Providers
      • Technology Providers

      By Deployment Model

      • Cloud-Based Model
      • Hybrid Model
      • On-Premises Model

      UK: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030

      Segment202220232024202520262027202820292030CAGR (%)
      ACADEMIC & RESEARCH INSTITUTIONS8.110.813.917.923.230.139.251.267.130
      GOVERNMENT & REGULATORY AGENCIES3.24.25.36.78.61114.118.223.528.2
      HEALTHCARE PAYERS22.73.54.45.77.49.612.516.329.5
      HEALTHCARE PROVIDERS3648.562.981.8106.7139.6183.3241.431931.1
      MEDICAL DEVICE/ EQUIPMENT COMPANIES7.19.411.915.219.525.132.341.854.328.7
      OTHER END USERS1.62.12.73.54.55.77.39.41228
      PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES1824.131.240.452.468.489.4117.2154.330.6
      TOTAL76101.8131.3169.9220.6287.3375.2491.7646.430.4

      Target Audience

      • Healthcare Technology Investors : UK-focused venture capital and private equity firms need detailed market sizing and growth projections to evaluate investment opportunities in AI oncology startups and established medtech companies operating in Britain.
      • Pharmaceutical & Medtech Companies : Multinational and UK-based pharmaceutical and medical device manufacturers require market intelligence to develop go-to-market strategies, identify partnership opportunities, and optimize product portfolios for the NHS and private sector.
      • NHS Trust Leadership : Hospital administrators, chief medical officers, and digital health directors need evidence-based market data to justify AI oncology investments, benchmark against peer institutions, and plan digital transformation roadmaps.
      • AI & Software Solution Providers : UK and international AI companies developing oncology solutions need market validation, competitive positioning data, and customer insights to refine product offerings and accelerate adoption across UK healthcare systems.
      • Healthcare Consultants & Analysts : Management consulting firms and healthcare research organizations require UK-specific market data to support client advisory work, strategic planning, and investment decision-making in the oncology AI sector.

      Reasons to Buy this Report

      • UK-Specific Market Sizing : Access precise valuation data for the UK market ($131.3M in 2024) with detailed forecasts through 2029, enabling accurate budget allocation and investment planning for UK-focused oncology AI initiatives.
      • Competitive Landscape Intelligence : Understand UK market dynamics, key players, and competitive positioning specific to the British healthcare system, NHS procurement processes, and regulatory environment for oncology AI solutions.
      • Growth Opportunity Identification : Identify high-potential segments within the UK market, including diagnostic AI, treatment planning, and patient monitoring, with insights into adoption rates across NHS trusts and private healthcare providers.
      • Regulatory & Reimbursement Insights : Gain comprehensive understanding of UK regulatory pathways, NICE approval processes, and NHS reimbursement models specific to AI oncology solutions, reducing market entry barriers.
      • Strategic Partnership Opportunities : Identify collaboration prospects with UK healthcare institutions, research centers, and technology providers to accelerate market penetration and establish strong footholds in the rapidly expanding British oncology AI sector.

      Frequently asked questions

      What is the current size of the UK AI in Oncology Market?

      The UK AI in Oncology Market was valued at $131.3 million in 2024 and is expected to grow significantly through 2029.

      What is the projected market size for the UK AI in Oncology Market by 2029?

      The UK AI in Oncology Market is forecast to reach $646.4 million by 2029, representing nearly five-fold growth from 2024.

      What is the CAGR for the UK AI in Oncology Market?

      The UK AI in Oncology Market is expected to grow at a compound annual growth rate of 30.4% between 2024 and 2029.

      What are the main drivers of growth in the UK AI in Oncology Market?

      Key growth drivers in the UK include rising cancer incidence, oncologist shortages, NHS digital transformation, government funding, and increasing adoption of AI-powered diagnostic and treatment solutions.

      How is the UK positioned compared to other European markets in AI oncology?

      The UK is a leading European market for AI oncology, driven by advanced healthcare infrastructure, strong regulatory support, and significant investment in precision medicine and digital health innovation.

      RESEARCH METHODOLOGY

      The study involved significant activities to estimate the current size of the AI in oncology. Exhaustive secondary research was done to collect information on the AI in oncology market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in oncology market.

      Secondary Research

      This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in oncology solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

      Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in oncology vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

      Primary Research

      In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in oncology market.

      After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in oncology solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

      In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

      Breakdown of Primary Participants:

      AI in Oncology Market

      Note 1: Others include sales managers, marketing managers, and product managers.

      Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in oncology. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry and markets have been identified through extensive secondary research.
      • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
      AI in Oncology Market

      Data Triangulation

      After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      AI I in oncology is the utilization of AI tools such as machine learning, natural language processing, and computer vision, among others to analyze genomic data and large gene mutations that are unique to an individual’s cancer profile. These AI tools are adopted by various end-users including labs, research centers, hospitals, and biotechnology & pharmaceuticals, among others to address the global cancer burden and the need for precision medicine in oncology.

      Further, AI boosts the speed and accuracy of cancer diagnosis and screening. The major developments include:

      • Pathologists can detect malignancy in prostate biopsy photos with the help of FDA-approved AI software.
      • AI quickly analyzes medical pictures, such as mammograms, increasing radiologists' productivity and enhancing risk assessment and detection of breast cancer.
      • Deep learning is used by NCI scientists to automatically detect precancerous cervical lesions as part of their efforts to improve cervical and prostate cancer screening.

      Stakeholders

      • Clinical/Physician Centers
      • AI Providers
      • Clinical Research Organizations
      • Pharmaceutical/Biopharmaceutical Companies
      • Research and Development (R&D) Companies
      • Business Research and Consulting Service Providers
      • Medical Research Laboratories
      • Academic Medical Centers/Universities/Hospitals
      • Government Agencies
      • Regulatory Agencies
      • Clinical Researchers
      • Clinical Research Organizations
      • Accountable Care Organizations
      • Investors and Venture Capitalists

      Report Objectives

      • To define, describe, and forecast the AI in oncology market based on player type, application, cancer type, technology, deployment model, end user, and region
      • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
      • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
      • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
      • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
      • To profile the key players and comprehensively analyze their market sizes and core competencies
      • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally

      Get the Full AI in Oncology Market Report

      Full forecast, segment splits, and company analysis for all AI in Oncology Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status